ABSTRACT

Dry eye syndrome is a multifactorial and prevalent ocular disease in elderly population that results in decrease quality of life. Dry eye syndrome is defined as a disease of tear film layer due to reduced tear production and/or tear film instability. Age-related alterations including eyelid laxity, meibomian gland disease and orifice metaplasia, decrease in tear volume result in dry eye. All ages may be suffered from Dry eye syndrome can be seen secondary to another eye diseases or systemic disease. This review will summarize the current knowledge about dry eye and therapeutic interventions being used to treat Dry eye syndrome.

Keywords: Dry eye syndrome; Aging; Sjögren's syndrome

KURU GÖZ SENDROMU: YAŞLANMA İLE ARTAN BİR PROBLEM

Öz

Kuru göz sendromu yaşlı popülsasyonda sık görülen ve yaşam kalitesinde azalma ile sonuçlanan multifaktöryel bir hastalıktır. Kuru göz sendromu azalması gözyaşı üretimi ve/veya gözyaşı film tabakasının kararsızlığı nedeni ile gelişen gözyaşı film tabakasının bir hastalığıdır. Göz kapaklarında gelişen meibomian bez hastalığı ve bez orifislerinde metaplasia, gözyaşı hacminde azalma gibi yaşa bağlı değişimler kuru göz sendromu türün yaşları etkileyebilmekte ve göz veya sistemik hastalıklara sekonder ortaya çıkmaktadır. Bu derlemenin amacı Kuru göz sendromu ile ilgili güncel bilginin ve günümüz tedavi yöntemlerinin özetlenmesidir.

Anahtar sözcükler: Kuru göz sendromu; Yaşlanma; Sjögren sendromu
INTRODUCTION

Dry eye syndrome (DES) is a multifactorial and prevalent ocular disease in elderly population that results in decrease quality of life. It is accompanied by increased osmolarity of the tear film and inflammation of the ocular surface. (1) DES is defined as a disease of tear film layer due to reduced tear production and/or tear film instability. All ages may be suffered from DES can be seen secondary to another eye diseases or systemic disease. Tear production is controlled by the LFU consisting of the ocular surface (conjunctiva, cornea, accessory lacrimal glands, and meibomian glands), the main lacrimal gland and the interconnecting innervation. (2) Any of these structures may be affected in DES.

Epidemiology

The Tear Film and Ocular Surface Society (TFOS) epidemiology subcommittee reviewed the prevalence, incidence, risk factors, natural history, morbidity and questionnaires reported in epidemiological studies of DES. (3) In 2007 Dry Eye Workshop (DEWS) group reported the prevalence of DES ranged from %5-30 in individuals over the age of 50. (4) Race is an important factor in the prevalence estimates of abnormal tear function. DES’s prevalence especially meibomian gland disease (MGD) appears to be higher in Asian than in Caucasian populations, increases with age, and women having a higher prevalence of dry eye than me. (5, 6) The Beaver Dam Eye Study established in a Caucasian population aged 48-91 that 13.3% (95% CI 12.0 -14.7%) of individuals developed symptomatic DES over 5 years and 21.6% (95% CI 19.9-23.3%) over 10 years. (7) Incidence was higher in women (25%) than men (17.3%) over the 10-year period after adjusting for age. Age was a risk factor for increased incidence, with an odds ratio of 1.2x (1.1-1.3) for each 10-year increment. (7)

The Singapore Malay Study and the Spanish Salnes Eye Study showed a higher rate of MGD in men. (8, 9) Interestingly DES is the relatively high prevalence rates reported in younger subjects and in school children, which support the potential risk factors such as digital device use. The Women’s Health Study, a study in which 25 665 postmenopausal women provided that women who use HRT, especially estrogen alone, are at increased risk of dry eye syndrome. (10)

Pathophysiology

Dysfunction of LFU results in bad quality and poor maintained tear film that causes ocular irritation symptoms and damage to the ocular surface. (11,12) The tear film is highly stabil and the stabil preocular tear film is important for cornea. In response to hyperosmolarity and surface cooling occurring in MGD-related DES, where the lacrimal gland is healthy, DES with a “wet dry eye”. (13) In TFOS-DEWS II report, tear film osmolarity is a central factor in the pathogenesis of aqueous deficiency and evaporative dry eye. (14) The risk factors for DES can be classified as high, moderate and low level of evidence. High level evidence risk factors including; age, female sex, postmenopausal estrogen therapy, antihistamines, collagen vascular disease, corneal refractive surgery, irradiation, hematopoietic stem cell transplantation, vitamin A deficiency, hepatitis C and androgen insufficiency, moderate level evidence risk factors including; medications such as tricyclic antidepressants, selective serotonin reuptake inhibitors, diuretics, beta-blockers, diabetes mellitus, HIV/HTLV1 infection, systemic chemotherapy, cataract surgery with a large incision, keratoplasty, isotretinoin, low air humidity, sarcoidosis, ovarian dysfunction and low level evidence risk factors are smoking, hispanic ethnicity, anticholinergic drugs such as anxiolytics, antipsychotics, topical anti-glaucomatous medications, alcohol, menopause, botulinum toxin injection, acne, gout, oral contraceptives, pregnancy. (15-18)

Symptoms of DES

Visual symptoms due to tear film instability and breakup, ocular discomfort, reduced lubrication, and neuropathic pain can be seen with DES. Slit
lamp examination may reveal duct dilatation and gland loss of meibomian glands, punctate epithelial keratopathy, filamentary keratitis, superior limbic keratoconjunctivitis, lid parallel conjunctival folds (LIPCOF) (Figure 1), and the lid margins changes.

**Figure 1.** The redundant conjunctival folds are located over the free edge of the lower eyelid and stained with fluorescein dye and cobalt light.

---

**Classification of DES**

Visual symptoms due to tear film instability and breakup, ocular discomfort, reduced lubrication, and neuropathic pain can be seen with DES. Slit lamp examination may reveal duct dilatation and gland loss of meibomian glands, punctate epithelial keratopathy, filamentary keratitis, superior limbic keratoconjunctivitis, lid parallel conjunctival folds (LIPCOF) (Figure 1), and the lid margins changes.

**I. Aqueous-deficient dry eye (ADDE)**

ADDE is included Sjögren syndrome dry eye (SSDE) and non-Sjögren syndrome dry eye (NSDE).

1. **Sjögren Syndrome and Sjögren Syndrome dry eye**

Sjögren syndrome (SS) is a chronic autoimmune disorder characterized by immune cell infiltration of exocrine glands and systemic complications due to autoantibody production, immune complex deposition and lymphocytic infiltration of many organ. (19, 20) Sjögren syndrome occurs predominantly in women, with a female/male ratio of 9:1, and it may lead to a very severe form of DES. (20-23) The lacrimal and salivary ducts are primary targets. Infiltration by T and B lymphocytes, dendritic cells, macrophages and other mononuclear cells, leading to tissue dysfunction or destruction. The loss of aqueous tear flow in Sjögren syndrome is a result of inflammatory cell infiltration of the lacrimal glands which leads to acinar and duct destruction. (19)

2. **Non-Sjögren Syndrome dry eye:**

   a. Age-related NSDE
   b. Congenital alacrima
   c. Familial dysautonomia
   d. Lacrimal gland infiltration (lymphoma, sarcoidosis, hemochromatosis, and amyloidosis)
   e. Viral infections (retroviruses, Epstein-Barr virus, human T-cell lymphotropic virus type 1, and human immunodeficiency virus (HIV), Hepatitis C virus (HCV))
   f. Hematopoietic stem cell transplants with or without the development of graft-versus-host disease: infiltration and fibrosis of the lacrimal glands and conjunctiva as a result of T-cell interaction with fibroblasts (20-30).

**II. Evaporative dry eye (EDE)**

1. **Lid-related evaporative dry eye (intrinsic EDE):**

   a. Age-related meibomian gland changes: meibomian gland drop out score is increasing after 40 years of age.
   b. The influence of sex hormones on meibomian gland function: Sjögren syndrome, antiandrogen treatment and complete androgen insensitivity syndrome, is associated with MGD, altered meibum lipid profiles and evidence of decreased tear film stability.
   c. Meibomian gland dysfunction: This is the
most common etiology of EDE. It must be distinguished from other meibomian gland diseases.

i. High meibum delivery state meibomian seborrhea: It is uncommon. This is associated with seborhoic dermatitis and rosacea. Acne Rosacea is a disease of eye and skin an is usually seen with fairly skinned individuals. Rosacea may be difficult to diagnose and differential diagnosis. Visualize telangiectasia or facial flushing are the skin findings and in eyes chronic recurrent blepharokeratoconjunctivitis, punctate erosions, peripheral keratitis, MGD, or recurrent chalazia are common findings. Children with ocular rosacea often present with corneal involve ment and asymmetry of ocular disease, and the potential for sight-threatening visual impairment should be considered.

ii. Low meibum delivery states - obstructive meibomian gland dysfunction: This is obstructive MGD and the most common type. TFOS Workshop on MGD, as follows and further details may be found in that report: “meibomian gland dysfunction (MGD) is a chronic, diffuse abnormality of the meibomian glands, commonly characterized by terminal duct obstruction and/or qualitative/quantitative changes in the glandular secretion. This may result in alteration of the tear film, symptoms of eye irritation, clinically apparent inflammation, and ocular surface disease”. MGD can be seen primary or secondary also cicatricial or noncicatricial.

3. Disorders of lid aperture, congruity and dynamics

a. Nocturnal lagophthalmos
b. Incomplete lid closure or lid deformity
c. An increase in palpebral fissure width or globe prominence exposes the tear film to greater evaporation
d. Parkinson’s disease and in progressive ophthalmoplegia

3. Ocular surface-related evaporative dry eye

a. Allergic eye disease
b. Vitamin A deficiency
c. Ocular surface disease due to topical agents (31-40).

Diagnosis of DES

Understanding characteristics of the causative factors, such as environments (air travel, sitting near an air conditioner vent, low humidity), prolonged visual efforts (reading, computer use), or symptomatic treatment with the use of artificial tears is helpful in diagnosing DES. A detailed review system examination must be done for any patient who has significant dry eye. Rheumatological system examination is important. For patients who are suspected of having Sjögren’s syndrome, a serological examination (Sjögren’s syndrome A antibody (SSA or anti-Ro), anti-Sjögren syndrome B antibody (SSB or anti-La), rheumatoid factor, and antinuclear antibody) should be ordered. Patients who might have thyroid eye disease should be tested for antithyroid peroxidase antibody and antithyroglobulin antibody. For standardization in clinical research, symptoms are typically taken through the use of questionnaire instruments that are most often self-administered by the patient or research subject without input from the clinician or researcher. Tear film breakup time, Schirmer test, ocular surface staining, tear film osmolarity, impression cytology, meibography, and in vivo confocal microscopy are the current diagnostic tests. (Figure 2).
Figure 2. Lissamine green staining of the ocular surface in a patient with dry eye syndrome secondary to Sjogrens Syndrome.

Treatment of DES

Staged Management And Treatment Recommendations For DES

First step of the management include education about the disease, modification of local environmental factors, dietary modifications (including oral essential fatty acid supplementation), identification and potential modification/elimination of offending systemic and topical medications. As treatment, ocular lubricants of various types (if MGD is present, then consider lipid-containing supplements), and lid hygiene and warm compresses comprise the treatment of mild DES. If the above options are inadequate, the second step of the treatment of DES incule non-preserved ocular lubricants to minimize preservative-induced toxicity, tea tree oil treatment for Demodex (if present) and inflammation, punctal occlusion and/or moisture chamber spectacles/goggles to tear conservation, and overnight treatments (such as ointment or moisture chamber devices). For inflammatory DES, such as Sjogrens Syndrome, the gold standard treatment options are anti-inflammatory agents including topical corticosteroid for limited-duration non-glucocorticoid immunomodulatory eye drops (such as cyclosporine and LFA-1 antagonist). For the severe DES, to protect the ocular surface, autologous/allogeneic serum eye drops, therapeutic contact lenses or some surgical procedures (tarsorrhaphy, amniotic membrane grafts) can be considered (41, 42).

REFERENCES

1. Craig JP, Nichols KK, Akpek EK, et al. TFOS DEWS II Definition and Classification Report. Ocul Surf 2017;15(3):276-283. (PMID:28736335).
2. Stern ME, Gao J, Siemasko KF, Beuerman RW, Pflugfelder SC. The role of the lacrimal functional unit in the pathophysiology of dry eye. Exp Eye Res 2004;78(3):409-16. (PMID:15106920).
3. Stapleton F, Alves M, Bunya VY, et al. TFOS DEWS II Epidemiology Report. Ocul Surf 2017;15(3):334-365. (PMID:28736337).
4. The epidemiology of dry eye disease: report of the Epidemiology Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf 2007;5(2):93-107. (PMID:17508117).
5. Millan A, Viso E, Gude F, Parafita-Fernandez A, Morana N, Rodriguez-Ares MT. Incidence and Risk Factors of Dry Eye in a Spanish Adult Population: 11-Year Follow-Up From the Salnes Eye Study. Cornea 2018;37(12):1527-1534. (PMID:30067536).
6. Song P, Xia W, Wang M, et al. Variations of dry eye disease prevalence by age, sex and geographic characteristics in China: a systematic review and meta-analysis. J Glob Health 2018;8(2):020503. (PMID:30206477).
7. Paulsen AJ, Cruickshanks KJ, Fischer ME, et al. Dry eye in the beaver dam offspring study: prevalence, risk factors, and health-related quality of life. Am J Ophthalmol 2014;157(4):799-806. (PMID:24388838).
8. Viso E, Rodriguez-Ares MT, Abelenda D, Oubina B, Gude F. Prevalence of asymptomatic and symptomatic meibomian gland dysfunction in the
9. Siak JJ, Tong L, Wong WL, et al. Prevalence and risk factors of meibomian gland dysfunction: the Singapore Malay eye study. Cornea 2012;31(11):1223-8. (PMID:22236788).

10. Sullivan BD, Crews LA, Sonmez B, et al. Clinical utility of objective tests for dry eye disease: variability over time and implications for clinical trials and disease management. Cornea 2012;31(9):1000-8. (PMID:22475641).

11. Sullivan DA, Buring JE, Sullivan DA, Dana MR. Hormone replacement therapy and dry eye syndrome. JAMA 2001;286(17):2114-9. (PMID:11694152).

12. Tsubota K. Tear dynamics and dry eye. Prog Retin Eye Res 1998;17(4):565-96. (PMID:9777650).

13. Schargus M, Geerling G. [The “wet” dry eye]. Ophthalmologe 2009;106(3):235-8: 240-1. (PMID:19242698).

14. Willcox MDP, Argueso P, Georgiev GA, et al. TFOS DEWS II Tear Film Report. Ocul Surf 2017;15(3):366-403. (PMID:28736338).

15. Messmer EM. The pathophysiology, diagnosis, and treatment of dry eye disease. Dtsch Arztebl Int 2015;112(5):71-81. (PMID:25686388).

16. Mocan MC, Uzunosmanoglu E, Kocabeyoglu S, Karakaya J, Irkec M. The Association of Chronic Topical Prostaglandin Analog Use With Meibomian Gland Dysfunction. J Glaucoma 2016;25(9):770-4. (PMID:27513901).

17. Schargus M, Ivanova S, Kakkassery V, Dick HB, Joachim S. Correlation of Tear Film Osmolarity and 2 Different MMP-9 Tests With Common Dry Eye Tests in a Cohort of Non-Dry Eye Patients. Cornea 2015;34(7):739-44. (PMID:25909238).

18. Krenzer KL, Dana MR, Ullman MD, et al. Effect of androgen deficiency on the human meibomian gland and ocular surface. J Clin Endocrinol Metab 2000;85(12):4874-82. (PMID:11134156).

19. Thompson N, Isenberg DA, Jury EC, Cuihn C. Exploring BAFF: its expression, receptors and contribution to the immunopathogenesis of Sjogren’s syndrome. Rheumatology (Oxford) 2016;55(9):1548-55. (PMID:26790457).

20. Akpek EK, Klimava A, Thorne JE, Martin D, Lekhanont K, Ostrovsky A. Evaluation of patients with dry eye for presence of underlying Sjogren syndrome. Cornea 2009;28(5):493-7. (PMID:19421051).

21. Pflugfelder SC, Jones D, Ji Z, Afnano A, Monroy D. Altered cytokine balance in the tear fluid and conjunctiva of patients with Sjogren’s syndrome keratoconjunctivitis sicca. Curr Eye Res 1999;19(3):201-11. (PMID:10487957).

22. The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf 2007;5(2):75-92. (PMID:17508116).

23. Rocha EM, Alves M, Rios JD, Dartt DA. The aging lacrimal gland: changes in structure and function. Ocul Surf 2008;6(4):162-74. (PMID:18829749).

24. Athappilly GK, Braverman RS. Congenital alacrima in a patient with blepharophimosis syndrome. Ophthalmic Genet 2009;30(1):37-9. (PMID:19172509).

25. Fox RI. Systemic diseases associated with dry eye. Int Ophthalmol Clin 1999;34(1):71-87. (PMID:8169074).

26. Merayo-Lloves J, Baltatzis S, Foster CS. Epstein-Barr virus dacryoadenitis resulting in keratoconjunctivitis sicca in a child. Am J Ophthalmol 2001;132(6):922-3. (PMID:11730660).

27. Itescu S. Diffuse infiltrative lymphocytosis syndrome in human immunodeficiency virus infection—a Sjogren’s-like disease. Rheum Dis Clin North Am 1991;17(1):99-115. (PMID:2041892).

28. Abe T, Nakajima A, Matsunaga M, Sakuragi S, Komatsu M. Decreased tear lactoferrin concentration in patients with chronic hepatitis C. Br J Ophthalmol 1999;83(6):684-7. (PMID:10340976).

29. Ogawa Y, Okamoto S, Wakui M, et al. Dry eye after haematopoietic stem cell transplantation. Br J Ophthalmol 1999;83(10):1125-30. (PMID:10502571).

30. Fei WL, Chen JQ, Du X, et al. [Dry eye in graft-versus-host disease]. Zhonghua Yan Ke Za Zhi 2003;39(11):686-90. (PMID:14766066).

31. Den S, Shimizu K, Ikeda T, Tsubota K, Shimura S, Shimazaki J. Association between meibomian gland changes and aging, sex, or tear function. Cornea 2006;25(6):651-5. (PMID:17077655).

32. Sullivan DA, Sullivan BD, Ullman MD, et al. Androgen influence on the meibomian gland. Invest Ophthalmol Vis Sci 2000;41(12):3732-42. (PMID:11053270).

33. Mathers WD. Ocular evaporation in meibomian gland dysfunction and dry eye. Ophthalmology 1993;100(3):347-51. (PMID:8460004).

34. Nichols KK, Foulks GN, Bron AJ, et al. The international workshop on meibomian gland dysfunction: executive
summary. Invest Ophthalmol Vis Sci 2011;52(4):1922-9. (PMID:21450913).

35. McCulley JP, Dougherty JM, Deneau DG. Classification of chronic blepharitis. Ophthalmology 1982;89(10):1173-80. (PMID:6218459).

36. Browning DJ, Rosenwasser G, Lugo M. Ocular rosacea in blacks. Am J Ophthalmol 1986;101(4):441-4. (PMID:2433782).

37. Berg M, Liden S. An epidemiological study of rosacea. Acta Derm Venereol 1989;69(5):419-23. (PMID:2748434).

38. Kellen R, Silverberg NB. Pediatric rosacea. Cutis 2016;98(1):49-53. (PMID:27529708).

39. Donaldson KE, Karp CL, Dunbar MT. Evaluation and treatment of children with ocular rosacea. Cornea 2007;26(1):42-6. (PMID:17198012).

40. Knop E, Knop N, Millar T, Obata H, Sullivan DA. The international workshop on meibomian gland dysfunction: report of the subcommittee on anatomy, physiology, and pathophysiology of the meibomian gland. Invest Ophthalmol Vis Sci 2011;52(4):1938-78. (PMID:21450915).

41. Foulks GN, Bron AJ. Meibomian gland dysfunction: a clinical scheme for description, diagnosis, classification, and grading. Ocul Surf 2003;1(3):107-26. (PMID:17075643).

42. Wang MTM, Xue AL, Craig JP. Screening utility of a rapid non-invasive dry eye assessment algorithm. Cont Lens Anterior Eye 2018;22(18):367-84. (PMID:30473321).